CAS: 714971-09-2; (S)-Morpholin-3-Ylmethyl (4-((1-(3-Fluorobenzyl)-1H-Indazol-5-yl)Amino)-5-Methylpyrrolo[2,1-F][1,2,4]Triazin-6-yl)Carbamate

上下游产品

CAS号714971-12-7 (S)-tert-butyl ...

5-氨基-1-(3-氟苄基)吲唑置于盐酸,Sodium Hydroxide,叠氮磷酸二苯酯,水,三乙胺,N,N-二异丙基乙胺体系中,用 四氢呋喃,甲醇,甲苯 作为反应溶剂,化学反应 4.0H,反应生成 [4-[[1-[(3-氟苯基)甲基]-1H-咪唑-5-基]氨基]-5-甲基吡咯[2,1-F][1,2,4]三嗪-6-基]-氨基甲酸-(3S)-3-吗啉甲酯
参考文献: Synthetic Process[fr] Procede De Synthese
标题: Synthetic Process[fr] Procede De Synthese

专利信息

专利号:US-11406709-B2
优先权日:2014-09-15
标 题 :Therapeutic and research application of PDCL3
发明人：RAHIMI NADER
权利人:UNIV BOSTON
摘要:Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.